A Phase 2 interventional study of Epinephrine Nasal Spray, 2.5 mg and Epinephrine Nasal Spray, 5.25 mg in Epinephrine, Hypersensitivity, Immediate and Anaphylaxis, sponsored by Hikma Pharmaceuticals USA Inc.. Not yet recruiting at 2 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Hikma Pharmaceuticals USA Inc. · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Anaphylaxis with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Anaphylaxis · United States.
Among the 26 studies in Anaphylaxis with a site in United States, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2, and was the 24th registered.
101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.
Browse Anaphylaxis studies →7 of the 26 studies in Anaphylaxis with a site in United States are open now. Recruiting first, the newest first:
Abigail Lang · Sites in United States
Ages 12–17
Mayo Clinic · Sites in United States
Ages 12+
Lumicell, Inc. · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–70
Food Allergy Research & Education · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Anaphylaxis studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is close to the median of 40 across 51 interventional studies indexed under Anaphylaxis.
Median enrollment 24 across the 12 interventional studies, 117 across the 14 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hikma Pharmaceuticals USA Inc., one of the names counted as Hikma Pharmaceuticals. Under that name alone:
This is the only study on the registry with Hikma Pharmaceuticals USA Inc. as lead sponsor.
Hikma Pharmaceuticals has 1 study filed under Anaphylaxis — fewer than ten, so there is no comparison to draw.
3 of the studies in Anaphylaxis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT07891780Hikma Pharmaceuticals USA Inc.Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients | 2027-05-08 |
| NCT04653324Food Allergy Research & EducationA Registry for the Food Allergy Community | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Anaphylaxis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2, open-label, single-arm study will evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose of epinephrine nasal spray (ENS) in children and adolescents 2 to 17 years of age with a diagnosed Type I allergy.
Approximately 44 participants will be enrolled in two body-weight cohorts.
The study will assess plasma epinephrine concentrations, changes in blood pressure and pulse rate, and safety and tolerability following administration of ENS. Participants will be monitored for 4 hours after dosing and will complete safety follow-up through approximately Day 15.
101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.
This study's planned enrollment of 44 is close to the median of 40 across 51 interventional studies indexed under Anaphylaxis.
Browse Anaphylaxis studies →This is the only study on the registry with Hikma Pharmaceuticals USA Inc. as lead sponsor.
Compared within Anaphylaxis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity, Immediate. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: acceptable highly effective methods of contraception include methods that can achieve a failure rate of less than 1% per year when used consistently and correctly: the intrauterine device; intrauterine system; bilateral tubal occlusion (must be documented); oral, intravaginal, transdermal, injectable, and implantable methods of hormonal contraception associated with inhibition of ovulation (combined estrogen and progesterone containing; or progesterone-only hormonal contraception); vasectomised partner (must be documented); or sexual abstinence (only when it is the usual and preferred lifestyle of the participant).
Note 1: Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraception method.
Note 2: Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the surgical success.
Note 3: In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the study participant
Exclusion Criteria:
Note: To account for stress-related elevations, if BP and/or PR are elevated on Day 1 pre-dose, the Investigator may consider repeating the measurement prior to participant exclusion. If BP and/or PR are elevated on repeated measurements, the participant should be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epinephrine Nasal Spray, 2.5 mg
Drug: Epinephrine Nasal Spray, 2.5 mg
Epinephrine Nasal Spray, 5.25 mg
Drug: Epinephrine Nasal Spray, 5.25 mg
A single dose of epinephrine nasal spray (ENS) will be administered intranasally based on body weight: 2.5 mg for participants weighing ≥15 to ≤30 kg.
A single dose of epinephrine nasal spray (ENS) will be administered intranasally based on body weight: 5.25 mg for participants weighing \>30 kg.
To assess the PK of a single dose of ENS in children and adolescents (2-17 years)
Epinephrine Maximal concentration (Cmax)
Time frame: 0-240 minutes
To assess the PK of a single dose of ENS in children and adolescents (2-17 years)
Time at maximal concentration (Tmax)
Time frame: 0-240 minutes
To assess the PK of a single dose of ENS in children and adolescents (2-17 years)
Area under the curve 0-240 min. (AUC0-240) based on observed plasma concentration-time data
Time frame: 0-240 minutes
To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)
Maximum effect (Emax) for Systolic blood pressure (SBP) until 240 min. post-dose.
Time frame: until 240 minutes post-dose
To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)
Maximum effect (Emax) for Diastolic blood pressure (DBP) until 240 min. post-dose.
Time frame: until 240 minutes post-dose
To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)
Maximum effect (Emax) for Pulse rate (PR) until 240 min. post-dose.
Time frame: until 240 minutes post-dose
To evaluate the PD of a single dose of ENS in children and adolescents (2-17 years)
Maximum effect (Emax) for Mean Arterial Pressure (MAP) until 240 min. post-dose.
Time frame: until 240 minutes post-dose
Occurrence of Treatment-emergent Adverse Events (TEAE) [Safety and Tolerability]
Occurrence of Treatment-emergent Adverse Events (TEAE) until Day 15, after a single dose of ENS in children and adolescents (2-17 years)
Time frame: 15 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for May 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.